递增式与个体化血液透析启动:一种新的诊疗标准
本研究在将递增式血液透析(iHD)作为透析启动标准的中心,观察2017至2021年全部158例新发血液透析患者,其中57.6%以iHD启动。与同中心既往数据及法国REIN登记倾向评分匹配队列比较,未发现生存差异,住院率与首次住院或死亡时间无差异,iHD-dHD策略节省16%费用,作者认为iHD可成为新的诊疗标准。
要点
- iHD可作为新发血液透析患者的一种安全可行的启动方式,最高可达三分之二的患者。
- 与标准透析方案相比,iHD-dHD策略未发现生存差异。
- iHD-dHD策略节省16%费用,即使计入补充生化检测。
核心结论
- 作者认为iHD可成为新的诊疗标准,因为其在新发血液透析患者中安全可行,最高可达三分之二的患者。
研究设计与样本
- 观察性研究,纳入2017至2021年全部新发血液透析患者158例,按透析启动方式分为iHD(每周1-2次)、dHD(起始每周3次后减少)或标准(每周3次)。
- 结果与同一单位递增式方案前(2015-2017年)记录的数据以及法国肾脏流行病学和信息网络(REIN)登记中倾向评分匹配队列进行比较。
主要发现
- 2017至2021年共158例患者启动血液透析,57.6%以iHD启动,8.9%以dHD启动,33.5%以标准透析方案启动。
- 标准透析方案组患者的初始估算肾小球滤过率(eGFR)更低(5 vs. 7 ml/min per 1.72 m2,P = 0.003)。
- 按启动时期(同中心)和倾向评分匹配(REIN)比较,未发现生存差异。
- 在透析前阶段接受密集随访的患者更可能以iHD-dHD启动。
- iHD-dHD的持续率1年时约为50%,2年时约为35%;各透析方案间的住院率和首次住院或死亡时间无差异。
临床怎么用
- 作者认为iHD可成为新的诊疗标准,因为其在新发血液透析患者中安全可行,最高可达三分之二的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Incremental hemodialysis (iHD) may attenuate "dialysis shock" and reduce costs, preserving quality of life. It is considered difficult to reconcile with HD wards' routine; fear of underdialysis and increasing mortality are additional concerns. The aim of this study was to evaluate mortality, morbidity, and costs in a large HD ward where iHD is the standard of HD start. METHODS: This observational study included all incident HD patients in 2017 to 2021, stratified according to HD start: iHD (1-2 sessions/wk), decremental HD (dHD, 3 sessions/wk at start, later reduced), or standard (3 sessions/wk). Results were compared with data recorded in the same unit before the incremental program (2015-2017) and with a propensity score-matched cohort from the French Renal Epidemiology and Information Network (REIN) registry. RESULTS: A total of 158 patients started HD in 2017 to 2021, 57.6% on iHD, 8.9% dHD, and 33.5% standard HD schedule. Patients on the standard schedule had lower initial estimated glomerular filtration rate (eGFR) (5 vs. 7 ml/min per 1.72 m2, P = 0.003). We found no survival differences according to period of start (same center) and propensity score matching (REIN). Patients intensively followed in the pre-HD period were more likely to start on iHD-dHD. Persistence on iHD-dHD was about 50% at 1 year and 35% at 2 years. Hospitalization rates and time to first hospitalization or death did not differ between the schedules. The iHD-dHD policy allowed a 16% cost saving, even accounting for supplemental biochemical tests. CONCLUSION: Our study reveals that iHD can be a new standard of care, as it is safe and feasible in up to two-thirds of patients on incident HD.
引用
- Torreggiani M, Fois A, Chatrenet A, et al. Incremental and Personalized Hemodialysis Start: A New Standard of Care. Kidney Int Rep. 2022. PMID: 35571001. doi:10.1016/j.ekir.2022.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。